
--- Page 1 ---
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
k191099
B Applicant
Atlas Medical
C Proprietary and Established Names
Atlas Multi-Drugs Screening Test Cup, Atlas Multi-Drugs Screening Test Panel
D Regulatory Information
Product Code(s) Classification Regulation Section Panel
DKZ Class II 21 CRF 862.3100 91 (Toxicology)
Amphetamine Test System
DIS Class II 21 CFR 862.3150 91 (Toxicology)
Barbiturate test system
JXM Class II 21 CFR 862.3170 91 (Toxicology)
Benzodiazepine test system
JXN Class II 21 CFR 862.3700 91 (Toxicology)
Propoxyphene Test System
DIO Class II 21 CFR 862.3250 Cocaine 91 (Toxicology)
and cocaine
metabolite test system
DJC Class II 21 CFR 862.3610 91 (Toxicology)
Methamphetamine test
system
DJR Class II 21 CFR 862.3620 91 (Toxicology)
Methadone test system
DJG Class II 21 CFR 862.3650 Opiate 91 (Toxicology)
test system
Unclassified, Enzyme immunoassay,
LCM 91 (Toxicology)
phencyclidine test system
LDJ Class II 21 CFR 862.3870 91 (Toxicology)
Cannabinoid test system
K191099 - Page 1 of 19

[Table 1 on page 1]
Product Code(s)	Classification	Regulation Section	Panel
DKZ	Class II	21 CRF 862.3100
Amphetamine Test System	91 (Toxicology)
DIS	Class II	21 CFR 862.3150
Barbiturate test system	91 (Toxicology)
JXM	Class II	21 CFR 862.3170
Benzodiazepine test system	91 (Toxicology)
JXN	Class II	21 CFR 862.3700
Propoxyphene Test System	91 (Toxicology)
DIO	Class II	21 CFR 862.3250 Cocaine
and cocaine
metabolite test system	91 (Toxicology)
DJC	Class II	21 CFR 862.3610
Methamphetamine test
system	91 (Toxicology)
DJR	Class II	21 CFR 862.3620
Methadone test system	91 (Toxicology)
DJG	Class II	21 CFR 862.3650 Opiate
test system	91 (Toxicology)
LCM	Unclassified, Enzyme immunoassay,
phencyclidine test system		91 (Toxicology)
LDJ	Class II	21 CFR 862.3870
Cannabinoid test system	91 (Toxicology)

--- Page 2 ---
Product Code(s) Classification Regulation Section Panel
LFG Class II 21 CFR 862.3910 Tricyclic 91 (Toxicology)
antidepressant drugs test
system
DNK Class II 21 CFR 862.3640 91 (Toxicology)
Morphine test system
II Submission/Device Overview:
A Purpose for Submission:
New device
B Measurand:
Amphetamine, Methylenedioxymethamphetamine, Morphine, Oxycodone, Cocaine,
Nortriptyline, Methamphetamine, Phencyclidine, Marijuana, Secobarbital, Oxazepam,
Methadone, Propoxyphene, and Buprenorphine.
C Type of Test:
Lateral flow chromatographic immunoassay
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
Atlas Multi-Drugs Screening Test Cup and Atlas Multi-Drugs Screening Test Panel are lateral
flow chromatographic in vitro diagnostics immunoassays for the qualitative detection of
following drugs in urine without the need of instruments:
Drug Name Calibrator Cut-off (ng/mL)
Amphetamine (AMP) D-Amphetamine 1000
Methylenedioxymethamphetamine D,LMethylenedioxymethamphetamine 500
(MDMA)
Morphine (MOP) Morphine 300
Morphine (MOP) Morphine 2000
Oxycodone (OXY) Oxycodone 100
Cocaine (COC) Benzoylecgonine 300
Nortriptyline Nortriptyline 1000
Methamphetamine (MET) D-Methamphetamine 1000
Phencyclidine (PCP) Phencyclidine 25
Marijuana (THC) 11-nor-Δ9-THC-9 COOH 50
Secobarbital Secobarbital 300
Oxazepam Oxazepam 300
Methadone (MTD) Methadone 300
Propoxyphene (PPX) Propoxyphene 300
Buprenorphine (BUP) Buprenorphine 10
K191099 - Page 2 of 19

[Table 1 on page 2]
Product Code(s)	Classification	Regulation Section	Panel
LFG	Class II	21 CFR 862.3910 Tricyclic
antidepressant drugs test
system	91 (Toxicology)
DNK	Class II	21 CFR 862.3640
Morphine test system	91 (Toxicology)

--- Page 3 ---
The tests are intended for professional use only. The tests will yield preliminary positive results
when the prescription drugs Secobarbital, oxazepam, Buprenorphine, Oxycodone,
Propoxyphene, and Nortriptyline are ingested, even at or above therapeutic doses. There are no
uniformly recognized drug levels for Secobarbital, oxazepam, Buprenorphine, Oxycodone,
Propoxyphene, and Nortriptyline in urine. The multi-drugs screening tests (Cup and Panel
formats) show the drug was or was not present at the cutoff level. The tests provide only
preliminary test results, which must be confirmed by other methods such as gas
chromatography/mass spectrometry (GC/MS). Clinical considerations and professional judgment
should be applied to any drug of abuse test result, particularly when preliminary positive results
are indicated. The tests are not intended to be used in monitoring the drug levels.
C Special Conditions for Use Statement(s):
Rx - For Prescription Use
D. Special Conditions for Use Statement(s):
None
IV Device/System Characteristics:
A Device Description:
The Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs Screening Test Panel are
competitive binding, lateral flow immunochromatographic assays for the qualitative detection of
the drugs of abuse, at the indicated cutoffs, stated in the indications for use. The tests can be
performed without the use of an instrument. The devices are available in one of two formats:
Test Cup and Dipcard. The test configurations consist of single drug screening tests or any
combinations of multiple drug screening tests.
B Principle of Operation:
The Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs Screening Test Panel are
immunoassays based on the principle of competitive binding. Drugs present in the urine
specimen compete against the drug conjugate for binding sites on the antibody. During testing, a
urine specimen migrates upward by capillary action. A drug, if present in the urine specimen
below its cut-off concentration, will not saturate the binding sites of its specific antibody. The
antibody will then react with the drug-protein conjugate and a visible colored line will show up
in the test line region of the specific drug strip. The presence of drug above the cut-off
concentration will saturate all the binding sites of the antibody. Therefore, the colored line will
not form in the test line region. A drug-positive urine specimen will not generate a colored line in
the specific test line region of the strip because of drug competition, while a drug-negative urine
specimen will generate a line in the test line region because of the absence of drug competition.
To serve as a procedural control, a colored line will always appear at the control line region,
indicating that proper volume of specimen has been added and membrane wicking has occurred.
V Substantial Equivalence Information:
A Predicate Device Name(s):
Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test Dipcard
K191099 - Page 3 of 19

--- Page 4 ---
B Predicate 510(k) Number(s):
k153050
C Comparison with Predicate(s):
Similarities
Item Candidate Device Predicate Device
(k191099) (k153050)
Atlas Multi-Drugs Screening Rapid Single/Multi-drug Test
Test panel Cup
Atlas Multi-Drugs Screening Rapid Single/Multi-drug Test
Test Cup Dipcard
Intended use For the qualitative detection Same
of drugs of abuse
Specimen type (Matrix) Urine Same
Methodology Colloidal Gold Immunoassay Same
(Membrane particle assay)
Test Time 5 minutes Same
Cut-off (ng/mL) AMP 1000 Same
MDMA 500 Same
Oxazepam 300 Same
BUP 10 Same
COC 300 Same
MET 1000 Same
MTD 300 Same
MOP 300 Same
MOP 2000 Same
OXY 100 Same
PCP 25 Same
PPX 300 Same
Nortriptyline 1000 Same
THC 50 Same
Secobarbital 300 Same
Differences
Item Candidate Device Predicate Device
(k191099) (k153050)
Atlas Multi-Drugs Screening Rapid Single/Multi-drug Test
Test panel Cup
Atlas Multi-Drugs Screening Rapid Single/Multi-drug Test
Test Cup Dipcard
Intended User Prescription Use Prescription and OTC use
Storage 2-30oC 4-30oC
K191099 - Page 4 of 19

[Table 1 on page 4]
Similarities		
Item	Candidate Device
(k191099)
Atlas Multi-Drugs Screening
Test panel
Atlas Multi-Drugs Screening
Test Cup	Predicate Device
(k153050)
Rapid Single/Multi-drug Test
Cup
Rapid Single/Multi-drug Test
Dipcard
Intended use	For the qualitative detection
of drugs of abuse	Same
Specimen type (Matrix)	Urine	Same
Methodology	Colloidal Gold Immunoassay
(Membrane particle assay)	Same
Test Time	5 minutes	Same
Cut-off (ng/mL)	AMP 1000	Same
	MDMA 500	Same
	Oxazepam 300	Same
	BUP 10	Same
	COC 300	Same
	MET 1000	Same
	MTD 300	Same
	MOP 300	Same
	MOP 2000	Same
	OXY 100	Same
	PCP 25	Same
	PPX 300	Same
	Nortriptyline 1000	Same
	THC 50	Same
	Secobarbital 300	Same

[Table 2 on page 4]
Differences		
Item	Candidate Device
(k191099)
Atlas Multi-Drugs Screening
Test panel
Atlas Multi-Drugs Screening
Test Cup	Predicate Device
(k153050)
Rapid Single/Multi-drug Test
Cup
Rapid Single/Multi-drug Test
Dipcard
Intended User	Prescription Use	Prescription and OTC use
Storage	2-30oC	4-30oC

--- Page 5 ---
VI Standards/Guidance Documents Referenced:
None referenced.
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
A precision study was conducted where three operators tested drug concentrations around the
cutoff, using spiked urine samples that were provided blind to the operators. Each operator
used devices from 3 different lots of the Atlas Multi-Drugs Screening Test Cup and the Atlas
Multi-Drugs Screening Test Panel, and the study was conducted over 2 weeks. For each
sample, 45 results were generated for each device. Results are provided in the table below.
Atlas Multi-Drugs Screening Test Panel Test Result:
Amphetamine (AMP) 1,000 ng/ml
Lot No. -100% -75% -50% -25% cut +25% +50% +75% +100%
cut off cut cut off cutoff off cut off cut off cut off cut off
off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Secobarbital 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Oxazepam 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Buprenorphine (BUP) 10 ng/ml
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Marijuana (THC) 50 ng/ml
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methadone (MTD) 300 ng/mL
K191099 - Page 5 of 19

[Table 1 on page 5]
Amphetamine (AMP) 1,000 ng/ml									
Lot No.	-100%
cut off	-75%
cut
off	-50%
cut off	-25%
cutoff	cut
off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Secobarbital 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Oxazepam 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Buprenorphine (BUP) 10 ng/ml									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Marijuana (THC) 50 ng/ml									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methadone (MTD) 300 ng/mL									

--- Page 6 ---
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methamphetamine (MET) 1,000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methylenedioxymethamphetamine (MDMA) 500 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Morphine (MOP 300) 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Morphine (MOP 2000) 2000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Oxycodone (OXY) 100ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Phencyclidine (PCP) 25 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Propoxyphene (PPX) 300ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
K191099 - Page 6 of 19

[Table 1 on page 6]
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methamphetamine (MET) 1,000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methylenedioxymethamphetamine (MDMA) 500 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Morphine (MOP 300) 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Morphine (MOP 2000) 2000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Oxycodone (OXY) 100ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Phencyclidine (PCP) 25 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Propoxyphene (PPX) 300ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-

--- Page 7 ---
Nortriptyline 1,000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Cocaine (COC) 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Atlas Multi-Drugs Screening Test Cup Test Result:
Amphetamine (AMP) 1,000 ng/ml
Lot No. -100% -75% -50% -25% cut +25% +50% +75% +100%
cut off cut cut off cutoff off cut off cut off cut off cut off
off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Secobarbital 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Oxazepam 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Buprenorphine (BUP) 10 ng/ml
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Marijuana (THC) 50 ng/ml
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methadone (MTD) 300 ng/mL
K191099 - Page 7 of 19

[Table 1 on page 7]
Nortriptyline 1,000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Cocaine (COC) 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-

[Table 2 on page 7]
Amphetamine (AMP) 1,000 ng/ml									
Lot No.	-100%
cut off	-75%
cut
off	-50%
cut off	-25%
cutoff	cut
off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Secobarbital 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Oxazepam 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Buprenorphine (BUP) 10 ng/ml									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Marijuana (THC) 50 ng/ml									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methadone (MTD) 300 ng/mL									

--- Page 8 ---
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methamphetamine (MET) 1,000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Methylenedioxymethamphetamine (MDMA) 500 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Morphine (MOP 300) 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Morphine (MOP 2000) 2000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cut off cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45-/0+
Oxycodone (OXY) 100ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Phencyclidine (PCP) 25 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Propoxyphene (PPX) 300ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
K191099 - Page 8 of 19

[Table 1 on page 8]
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methamphetamine (MET) 1,000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Methylenedioxymethamphetamine (MDMA) 500 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Morphine (MOP 300) 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Morphine (MOP 2000) 2000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cut off	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+	45-/0+
Oxycodone (OXY) 100ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Phencyclidine (PCP) 25 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Propoxyphene (PPX) 300ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-

--- Page 9 ---
Nortriptyline 1,000 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Cocaine (COC) 300 ng/mL
Lot No. -100% -75% -50% -25% cut off +25% +50% +75% +100%
cut off cut off cut off cutoff cut off cut off cut off cut off
Lot A 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot B 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
Lot C 45-/0+ 45-/0+ 45-/0+ 45-/0+ 45+/0- 45+/0- 45+/0- 45+/0- 45+/0-
2. Linearity:
Not applicable.
3. Analytical Specificity/Interference:
Cross-reactivity:
Cross reactivity with structurally similar compounds was tested for each device, and the
results for both devices were identical, as provided in the table below. The table below lists
the concentrations at which various compounds produced a positive result, or the maximum
concentration detected, and these concentrations were used to calculate the percent (%)
cross-reactivity.
Drug Name
AMPHETAMINE 1000 ng/mL % of cross
reactivity
D-Amphetamine 1000 100%
D, L-Amphetamine 2500 40%
L-Amphetamine 50000 2%
(+/-)3,4-Methylenedioxy-amphetamine (MDA) 2000 50%
Ephedrine > 100000 >1%
3,4-Methylenedioxythylamphetamine (MDEA) > 100000 >1%
MDMA 1000 100%
D-Methamphetamine 1500 66.7%
L- Methamphetamine 3500 28.5%
SECOBARBITAL 300 ng/mL % of cross
reactivity
Secobarbital 300 100%
Phenobarbital 2500 12%
Butalbital 500 60%
Pentobarbital 1500 20%
Amobarbital 2500 12%
K191099 - Page 9 of 19

[Table 1 on page 9]
Nortriptyline 1,000 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Cocaine (COC) 300 ng/mL									
Lot No.	-100%
cut off	-75%
cut off	-50%
cut off	-25%
cutoff	cut off	+25%
cut off	+50%
cut off	+75%
cut off	+100%
cut off
Lot A	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot B	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-
Lot C	45-/0+	45-/0+	45-/0+	45-/0+	45+/0-	45+/0-	45+/0-	45+/0-	45+/0-

[Table 2 on page 9]
Drug Name		
AMPHETAMINE 1000	ng/mL	% of cross
reactivity
D-Amphetamine	1000	100%
D, L-Amphetamine	2500	40%
L-Amphetamine	50000	2%
(+/-)3,4-Methylenedioxy-amphetamine (MDA)	2000	50%
Ephedrine	> 100000	>1%
3,4-Methylenedioxythylamphetamine (MDEA)	> 100000	>1%
MDMA	1000	100%
D-Methamphetamine	1500	66.7%
L- Methamphetamine	3500	28.5%

[Table 3 on page 9]
SECOBARBITAL 300	ng/mL	% of cross
reactivity
Secobarbital	300	100%
Phenobarbital	2500	12%
Butalbital	500	60%
Pentobarbital	1500	20%
Amobarbital	2500	12%

--- Page 10 ---
SECOBARBITAL 300 ng/mL % of cross
reactivity
Cyclopentobarbital 500 60%
Butethal 800 37.5%
Barbital 300 100%
Butabarbital 1500 20%
Buprenorphine 10 ng/mL % of cross
reactivity
Buprenorphine 10 100%
Norbuprenorphine 15 66.7%
Buprenorphine 3-D-Glucuronide 12.5 80%
Norbuprenorphine 3-D-Glucuronide 175 5.7%
Morphine-3-D-glucoronide 100000 0.01%
Morphine > 100000 >0.01%
Oxymorphone > 100000 >0.01%
Hydromorphone > 100000 >0.01%
OXAZEPAM 300 ng/mL % of cross
reactivity
Oxazepam 300 100%
Alprazolam 200 150%
α-Hydroxyalprazolam 1000 30%
Bromazepam 250 120%
Chlordiazepoxide 2500 12%
Clobazam 100 300%
Clonazepam 850 35.3%
Clorazepate 250 120%
Delorazepam 1600 18.75%
Diazepam 200 150%
Estazolam 200 150%
Flunitrazepam 300 100%
Lorazepam 1000 30%
Midazolam 1500 20%
Nitrazepam 100 300%
Nordiazepam 400 75%
Temazepam 150 200%
Triazolam 500 60%
K191099 - Page 10 of 19

[Table 1 on page 10]
SECOBARBITAL 300	ng/mL	% of cross
reactivity
Cyclopentobarbital	500	60%
Butethal	800	37.5%
Barbital	300	100%
Butabarbital	1500	20%

[Table 2 on page 10]
Buprenorphine 10	ng/mL	% of cross
reactivity
Buprenorphine	10	100%
Norbuprenorphine	15	66.7%
Buprenorphine 3-D-Glucuronide	12.5	80%
Norbuprenorphine 3-D-Glucuronide	175	5.7%
Morphine-3-D-glucoronide	100000	0.01%
Morphine	> 100000	>0.01%
Oxymorphone	> 100000	>0.01%
Hydromorphone	> 100000	>0.01%

[Table 3 on page 10]
OXAZEPAM 300	ng/mL	% of cross
reactivity
Oxazepam	300	100%
Alprazolam	200	150%
α-Hydroxyalprazolam	1000	30%
Bromazepam	250	120%
Chlordiazepoxide	2500	12%
Clobazam	100	300%
Clonazepam	850	35.3%
Clorazepate	250	120%
Delorazepam	1600	18.75%
Diazepam	200	150%
Estazolam	200	150%
Flunitrazepam	300	100%
Lorazepam	1000	30%
Midazolam	1500	20%
Nitrazepam	100	300%
Nordiazepam	400	75%
Temazepam	150	200%
Triazolam	500	60%

--- Page 11 ---
COCAINE 300 ng/mL % of cross
reactivity
Cocaine > 100000 >0.3%
Benzoylecgonine 300 100%
EcgonineHCl 35000 0.86%
Coaethylene 14000 2.14%
Norcocaine > 100000 >0.3%
METHADONE 300 ng/mL % of cross
reactivity
Methadone 300 100%
(+)2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium 50000 0.6%
Doxylamine 50000 0.6%
EMDP (2-Ethyl-5-methyl-3,3-diphenylpyrroline) > 100000 >0.3%
LAAM (1-Alpha-acetylmethadol) 5000 6%
α- Methadol 2000 15%
Disopyramide 8000 3.75%
METHAMPHETAMINES 1000 ng/mL % of cross
reactivity
(+/-)- Methamphetamine 2000 50%
(+)-Methamphetamine 1000 100%
3,4-Methylenedioxythylamphetamine (MDEA) 35000 2.85%
(+/-) 3,4-Methylenedioxymethamphetamine (MDMA) 2000 50%
Ranitidine (Zantac) > 100000 >1%
3,4-Methylenedioxyamphetamine (MDA) > 100000 >1%
D-Amphetamine > 100000 >1%
L-Amphetamine > 100000 >1%
Ephedrine > 100000 >1%
L-Methamphetamine 5000 20%
METHYLENEDIOXYMETHAMPHETAMINE ng/mL % of cross
(MDMA) 500 reactivity
(+/-) 3,4-Methylenedioxymethamphetamine (MDMA) 500 100%
D-Amphetamine > 100000 > 0.5%
L-Methamphetamine 100000 0.5%
3,4-Methylenedioxythylamphetamine (MDEA) 200 250%
3,4-Methylenedioxyamphetamine (MDA) 2000 25%
L-Amphetamine > 100000 > 0.5%
D-Methamphetamine > 100000 > 0.5%
K191099 - Page 11 of 19

[Table 1 on page 11]
COCAINE 300	ng/mL	% of cross
reactivity
Cocaine	> 100000	>0.3%
Benzoylecgonine	300	100%
EcgonineHCl	35000	0.86%
Coaethylene	14000	2.14%
Norcocaine	> 100000	>0.3%

[Table 2 on page 11]
METHADONE 300	ng/mL	% of cross
reactivity
Methadone	300	100%
(+)2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium	50000	0.6%
Doxylamine	50000	0.6%
EMDP (2-Ethyl-5-methyl-3,3-diphenylpyrroline)	> 100000	>0.3%
LAAM (1-Alpha-acetylmethadol)	5000	6%
α- Methadol	2000	15%
Disopyramide	8000	3.75%

[Table 3 on page 11]
METHAMPHETAMINES 1000	ng/mL	% of cross
reactivity
(+/-)- Methamphetamine	2000	50%
(+)-Methamphetamine	1000	100%
3,4-Methylenedioxythylamphetamine (MDEA)	35000	2.85%
(+/-) 3,4-Methylenedioxymethamphetamine (MDMA)	2000	50%
Ranitidine (Zantac)	> 100000	>1%
3,4-Methylenedioxyamphetamine (MDA)	> 100000	>1%
D-Amphetamine	> 100000	>1%
L-Amphetamine	> 100000	>1%
Ephedrine	> 100000	>1%
L-Methamphetamine	5000	20%

[Table 4 on page 11]
METHYLENEDIOXYMETHAMPHETAMINE
(MDMA) 500	ng/mL	% of cross
reactivity
(+/-) 3,4-Methylenedioxymethamphetamine (MDMA)	500	100%
D-Amphetamine	> 100000	> 0.5%
L-Methamphetamine	100000	0.5%
3,4-Methylenedioxythylamphetamine (MDEA)	200	250%
3,4-Methylenedioxyamphetamine (MDA)	2000	25%
L-Amphetamine	> 100000	> 0.5%
D-Methamphetamine	> 100000	> 0.5%

--- Page 12 ---
MARIJUANA 50 ng/mL % of cross
reactivity
11-nor-D9 -THC-9 COOH 50 100%
11-nor-D8-THC-9 COOH 50 100%
D8 -THC 8000 0.6%
D9 -THC 10000 0.5%
Cannabinol 100000 0.05%
% of cross
MORPHINE 2000 ng/mL reactivity
Morphine 2000 100%
Codeine 2000 100%
Hydrocodone 10000 20%
Hydromorphone 7000 28.5%
Morphine 3-b-D-glucuronide 2000 100%
6-Monoacetylmorphine 5000 40%
Normorphone 100000 2%
Oxycodone 20000 10%
Oxymorphone 100000 2%
Thebaine 70000 2.8%
Heroin 2500 80%
Ethylmorphine 5000 40%
% of cross
MORPHINE 300 ng/mL reactivity
Morphine 300 100%
Codeine 300 100%
Hydrocodone 2000 15%
Hydromorphone 3500 8.5%
Morphine 3-b-D-glucuronide 300 100%
6-Monoacetylmorphine 600 50%
Normorphone 100000 0.3%
Oxycodone 10000 3%
Oxymorphone 50000 0.6%
Thebaine 7000 4.3%
Heroin 350 85.7%
Ethylmorphine 6000 5%
K191099 - Page 12 of 19

[Table 1 on page 12]
MARIJUANA 50	ng/mL	% of cross
reactivity
11-nor-D9 -THC-9 COOH	50	100%
11-nor-D8-THC-9 COOH	50	100%
D8 -THC	8000	0.6%
D9 -THC	10000	0.5%
Cannabinol	100000	0.05%

[Table 2 on page 12]
MORPHINE 2000	ng/mL	% of cross
reactivity
Morphine	2000	100%
Codeine	2000	100%
Hydrocodone	10000	20%
Hydromorphone	7000	28.5%
Morphine 3-b-D-glucuronide	2000	100%
6-Monoacetylmorphine	5000	40%
Normorphone	100000	2%
Oxycodone	20000	10%
Oxymorphone	100000	2%
Thebaine	70000	2.8%
Heroin	2500	80%
Ethylmorphine	5000	40%

[Table 3 on page 12]
MORPHINE 300	ng/mL	% of cross
reactivity
Morphine	300	100%
Codeine	300	100%
Hydrocodone	2000	15%
Hydromorphone	3500	8.5%
Morphine 3-b-D-glucuronide	300	100%
6-Monoacetylmorphine	600	50%
Normorphone	100000	0.3%
Oxycodone	10000	3%
Oxymorphone	50000	0.6%
Thebaine	7000	4.3%
Heroin	350	85.7%
Ethylmorphine	6000	5%

--- Page 13 ---
% of cross
OXYCODONE 100 ng/mL reactivity
Oxycodone 100 100%
Morphine 50000 0.2%
Codeine 25000 0.4%
Morphine 3-b-D-glucuronide 50000 0.2%
Hydrocodone 1600 6.25%
Hydromorphone 15000 0.67%
Normorphone 100000 0.1%
Oxymorphone 1500 6.7%
6-Monoacetylmorphine >100000 >0.1%
Ethylmorphine 5000 2%
% of cross
PHENCYCLIDINE 25 ng/mL reactivity
Phencyclidine 25 100%
4-Hydroxyphencyclidine 15000 0.17%
% of cross
PROPOXYPHENE 300 ng/mL reactivity
propoxyphene 300 100%
Norpropoxyphene 7500 4%
Methadone > 100000 0.3%
% of cross
NORTRIPTYLINE 1000 ng/mL reactivity
Nortriptyline 1000 100%
Trimipramine 4500 22.2%
Amitriptyline 1000 100%
Promazine 3000 33.3%
Desipramine 1000 100%
Imipramine 1000 100%
Clomipramine 7500 13.3%
Doxepine 3000 33.3%
Maprotiline 50000 2%
Interference:
Interference from structurally similar and dissimilar compounds was evaluated by spiking these
compounds into urine samples containing drugs of abuse at concentrations of +/-25% of the
respective cut-offs. The following list of potentially interfering substances showed no
interference at a test concentration of 100 ug/ml (albumin was evaluated at 20 mg/mL) when
tested with Atlas Multi-Drugs Screening Test Panel and Atlas Multi-Drugs Screening Test cup.
K191099 - Page 13 of 19

[Table 1 on page 13]
OXYCODONE 100	ng/mL	% of cross
reactivity
Oxycodone	100	100%
Morphine	50000	0.2%
Codeine	25000	0.4%
Morphine 3-b-D-glucuronide	50000	0.2%
Hydrocodone	1600	6.25%
Hydromorphone	15000	0.67%
Normorphone	100000	0.1%
Oxymorphone	1500	6.7%
6-Monoacetylmorphine	>100000	>0.1%
Ethylmorphine	5000	2%

[Table 2 on page 13]
PHENCYCLIDINE 25	ng/mL	% of cross
reactivity
Phencyclidine	25	100%
4-Hydroxyphencyclidine	15000	0.17%

[Table 3 on page 13]
PROPOXYPHENE 300	ng/mL	% of cross
reactivity
propoxyphene	300	100%
Norpropoxyphene	7500	4%
Methadone	> 100000	0.3%

[Table 4 on page 13]
NORTRIPTYLINE 1000	ng/mL	% of cross
reactivity
Nortriptyline	1000	100%
Trimipramine	4500	22.2%
Amitriptyline	1000	100%
Promazine	3000	33.3%
Desipramine	1000	100%
Imipramine	1000	100%
Clomipramine	7500	13.3%
Doxepine	3000	33.3%
Maprotiline	50000	2%

--- Page 14 ---
Acetophenetidin Estrone-3-sulfate Penicillin-G
Acetone Ethyl alcohol Perphenazine
N-Acetylprocainamide L-ψ-Ephedrine Phenelzine
Acetylsalicylic acid Fenoprofen L-Phenylephrine
Acetaminophen Furosemide b-Phenylethylamine
Albumin Gentisic acid Pheniramine
Aminopyrine d-Glucose Phenothiazine
Amoxicillin Guaiacol Glyceryl Ether Prednisolone
Ampicillin Hemoglobin Prednisone
L-Ascorbic acid Hydralazine Procaine
Apomorphine Hydrochlorothiazide DL-Propranolol
Aspartame Hydrocortisone D-Pseudoephedrine
Atropine O-Hydroxyhippuric acid Quinidine
Benzilic acid Ibuprofen Quinine
Benzoic acid D, L-Isoproterenol Ranitidine
Bilirubin Isoxsuprine Riboflavin
Caffeine Ketamine Salicylic acid
Cannabidiol Ketoprofen Serotonin
Chloralhydrate Labetalol Sodium chloride
Chloramphenicol Lidocaine Sulfamethazine
Chlorothiazide Loperamide Sulindac
(+) Chlorpheniramine Meperidine Tetracycline
Chlorprothixene Meprobamate Tetrahydrocortisone, 3-acetate
Chloroquine Methoxyphenamine Tetrahydrozoline
Cholesterol Methylphenidate Thiamine
Clonidine Nalidixic acid Theophylline
Cortisone Naloxone Tolbutamide
L- Cotinine Naltrexone Triamterene
Creatinine Naproxen Trifluoperazine
Deoxycorticosterone Niacinamide Trimethoprim
Dextromethorphan Nifedipine DL-Tryptophan
Dexbrompheniramine Nicotine Verapamil
Diclofenac Norethindrone Zomepirac
Diflunisal Noscapine (R,2S)-(-)-N-Methyl-Ephedrine
Digoxin Norephedrine
4-Dimethylaminoantipyrine d,l-Octopamine
Diphenhydramine Oxalic acid
Dopamine Oxolinic acid
Erythromycin Oxymetazoline
b-Estradiol Papaverine
K191099 - Page 14 of 19

[Table 1 on page 14]
Acetophenetidin	Estrone-3-sulfate	Penicillin-G
Acetone	Ethyl alcohol	Perphenazine
N-Acetylprocainamide	L-ψ-Ephedrine	Phenelzine
Acetylsalicylic acid	Fenoprofen	L-Phenylephrine
Acetaminophen	Furosemide	b-Phenylethylamine
Albumin	Gentisic acid	Pheniramine
Aminopyrine	d-Glucose	Phenothiazine
Amoxicillin	Guaiacol Glyceryl Ether	Prednisolone
Ampicillin	Hemoglobin	Prednisone
L-Ascorbic acid	Hydralazine	Procaine
Apomorphine	Hydrochlorothiazide	DL-Propranolol
Aspartame	Hydrocortisone	D-Pseudoephedrine
Atropine	O-Hydroxyhippuric acid	Quinidine
Benzilic acid	Ibuprofen	Quinine
Benzoic acid	D, L-Isoproterenol	Ranitidine
Bilirubin	Isoxsuprine	Riboflavin
Caffeine	Ketamine	Salicylic acid
Cannabidiol	Ketoprofen	Serotonin
Chloralhydrate	Labetalol	Sodium chloride
Chloramphenicol	Lidocaine	Sulfamethazine
Chlorothiazide	Loperamide	Sulindac
(+) Chlorpheniramine	Meperidine	Tetracycline
Chlorprothixene	Meprobamate	Tetrahydrocortisone, 3-acetate
Chloroquine	Methoxyphenamine	Tetrahydrozoline
Cholesterol	Methylphenidate	Thiamine
Clonidine	Nalidixic acid	Theophylline
Cortisone	Naloxone	Tolbutamide
L- Cotinine	Naltrexone	Triamterene
Creatinine	Naproxen	Trifluoperazine
Deoxycorticosterone	Niacinamide	Trimethoprim
Dextromethorphan	Nifedipine	DL-Tryptophan
Dexbrompheniramine	Nicotine	Verapamil
Diclofenac	Norethindrone	Zomepirac
Diflunisal	Noscapine	(R,2S)-(-)-N-Methyl-Ephedrine
Digoxin	Norephedrine	
4-Dimethylaminoantipyrine	d,l-Octopamine	
Diphenhydramine	Oxalic acid	
Dopamine	Oxolinic acid	
Erythromycin	Oxymetazoline	
b-Estradiol	Papaverine	

--- Page 15 ---
Effect of pH on the Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs
Screening Test Panel:
The pH of drug-free urine samples was adjusted to be pH 4.5, 5, 6, 7, 8 and 9, and the samples
were spiked with drugs of abuse to +/-25% and +/-50% of the respective cutoffs. Each sample
was tested using the Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs Screening
Test Panel. The results demonstrated that the pH does not affect the results of the Atlas Multi-
Drugs Screening Test Cup and the Atlas Multi-Drugs Screening Test Panels.
Effect of specific gravity on the Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-
Drugs Screening Test Panel:
The specific gravity of drug-free urine samples was adjusted to 1.005, 1.010, 1.015, 1.025 and
1.030 and spiked with drugs of abuse to +/-25% and +/-50% of the respective cutoffs. Each
sample was tested using the Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs
Screening Test Panel. The results demonstrated that the specific gravity does not affect the
results of the Atlas Multi-Drugs Screening Test Cup and the Atlas Multi-Drugs Screening Test
Panel.
4. Assay Reportable Range:
Not applicable.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Not applicable.
6. Detection Limit:
Not applicable.
7. Assay Cut-Off:
See section VII.A.1.
B Comparison Studies:
1. Accuracy
A method comparison study was conducted to demonstrate the accuracy of the Atlas Multi-
Drugs Screening Test Cup and the Atlas Multi-Drugs Screening Test Panel with the GC/MS
or LC/MS methods. Testing was performed on 80 unaltered clinical specimens for each test
analyte (except for PCP samples which were diluted as per the table mentioned below in the
study due to difficulty in sourcing PCP native samples). The unaltered clinical samples were
quantitated with GC/MS or LC/MS and were also tested using the Atlas Multi-Drugs
Screening Test Cup and the Atlas Multi-Drugs Screening Test Panel. Test results per drug
analyte are summarized in the table below:
K191099 - Page 15 of 19

--- Page 16 ---
1) Atlas Multi-Drugs Screening Test Panel Test Result:
Tested Drug Candidate Negative Less than Near cutoff Near cutoff High Positive
Device samples half the negative positive (greater than
Result cutoff (between - (between the +50% above
concentratio 50% below the cutoff the cutoff
n by GC/MS cutoff and the and+50% concentration)
cutoff Above the
concentration) cutoff
concentration)
AMP 1000 Positive 0 0 1 4 36
Negative 16 20 3 0 0
Secobarbital Positive 0 0 1 2 37
300 Negative 18 17 4 1 0
Oxazepam Positive 0 0 2 3 36
300 Negative 19 17 2 1 0
COC 300 Positive 0 0 1 3 37
Negative 20 15 4 0 0
THC 50 Positive 0 0 0 2 36
Negative 21 15 4 2 0
MTD 300 Positive 0 0 1 2 37
Negative 18 17 4 1 0
MET 1000 Positive 0 0 2 3 36
Negative 22 14 2 1 0
MDMA 500 Positive 0 0 1 4 36
Negative 25 11 3 0 0
MOP 300 Positive 0 0 1 2 37
Negative 21 14 4 1 0
MOP 2000 Positive 0 0 0 4 35
Negative 20 17 3 1 0
PPX 300 Positive 0 0 1 2 36
Negative 25 11 3 2 0
OXY 100 Positive 0 0 1 3 37
Negative 21 14 4 0 0
Nortriptylin Positive 0 0 0 2 36
e Negative 22 14 4 2 0
1000
BUP 10 Positive 0 0 0 2 36
Negative 21 15 4 2 0
PCP 25 Positive 0 0 2 3 16
Negative 20 16 4 0 0
2) Atlas Multi-Drugs Screening Test Cup Test Result:
Tested Candidate Negative Less than Near cutoff Near cutoff High Positive
Drug Device samples half the negative positive (greater than
Result cutoff (between - (between the +50% above
concentratio 50% below the cutoff the cutoff
n by GC/MS cutoff and the and+50% concentration)
cutoff Above the
concentration)
K191099 - Page 16 of 19

[Table 1 on page 16]
Tested Drug	Candidate
Device
Result	Negative
samples	Less than
half the
cutoff
concentratio
n by GC/MS	Near cutoff
negative
(between -
50% below the
cutoff and the
cutoff
concentration)	Near cutoff
positive
(between the
cutoff
and+50%
Above the
cutoff
concentration)	High Positive
(greater than
+50% above
the cutoff
concentration)
AMP 1000	Positive	0	0	1	4	36
	Negative	16	20	3	0	0
Secobarbital
300	Positive	0	0	1	2	37
	Negative	18	17	4	1	0
Oxazepam
300	Positive	0	0	2	3	36
	Negative	19	17	2	1	0
COC 300	Positive	0	0	1	3	37
	Negative	20	15	4	0	0
THC 50	Positive	0	0	0	2	36
	Negative	21	15	4	2	0
MTD 300	Positive	0	0	1	2	37
	Negative	18	17	4	1	0
MET 1000	Positive	0	0	2	3	36
	Negative	22	14	2	1	0
MDMA 500	Positive	0	0	1	4	36
	Negative	25	11	3	0	0
MOP 300	Positive	0	0	1	2	37
	Negative	21	14	4	1	0
MOP 2000	Positive	0	0	0	4	35
	Negative	20	17	3	1	0
PPX 300	Positive	0	0	1	2	36
	Negative	25	11	3	2	0
OXY 100	Positive	0	0	1	3	37
	Negative	21	14	4	0	0
Nortriptylin
e
1000	Positive	0	0	0	2	36
	Negative	22	14	4	2	0
BUP 10	Positive	0	0	0	2	36
	Negative	21	15	4	2	0
PCP 25	Positive	0	0	2	3	16
	Negative	20	16	4	0	0

[Table 2 on page 16]
Tested
Drug	Candidate
Device
Result	Negative
samples	Less than
half the
cutoff
concentratio
n by GC/MS	Near cutoff
negative
(between -
50% below the
cutoff and the
cutoff
concentration)	Near cutoff
positive
(between the
cutoff
and+50%
Above the	High Positive
(greater than
+50% above
the cutoff
concentration)

--- Page 17 ---
cutoff
concentration)
AMP 1000 Positive 0 0 1 4 36
Negative 16 20 3 0 0
Secobarbital Positive 0 0 1 2 37
300 Negative 18 17 4 1 0
Oxazepam Positive 0 0 2 3 36
300 Negative 19 17 2 1 0
COC 300 Positive 0 0 1 3 37
Negative 20 15 4 0 0
THC 50 Positive 0 0 0 2 36
Negative 21 15 4 2 0
MTD 300 Positive 0 0 1 2 37
Negative 18 17 4 1 0
MET 1000 Positive 0 0 2 3 36
Negative 22 14 2 1 0
MDMA 500 Positive 0 0 1 4 36
Negative 25 11 3 0 0
MOP 300 Positive 0 0 1 2 37
Negative 21 14 4 1 0
MOP 2000 Positive 0 0 0 4 35
Negative 20 17 3 1 0
PPX 300 Positive 0 0 1 2 36
Negative 25 11 3 2 0
OXY 100 Positive 0 0 1 3 37
Negative 21 14 4 0 0
Nortriptylin Positive 0 0 0 2 36
e 1000 Negative 23 13 4 2 0
BUP 10 Positive 0 0 0 2 36
Negative 21 15 4 2 0
PCP 25 Positive 0 0 2 3 16
Negative 20 16 4 0 0
The Summary of Discordant Results is listed in the table below:
Tested Drug Cut-off Sample Number LC/MS Atlas Multi – Atlas Multi –
Result Screening DOA Screening DOA
panel Test Cup Test
Results Results
AMP 1000 Sample 23 855 Positive Positive
Secobarbital 300 Sample 51 287 Positive Positive
Secobarbital 300 Sample 71 348 Negative Negative
Oxazepam 300 Sample 16 330 Negative Negative
Oxazepam 300 Sample 37 299 Positive Positive
Oxazepam 300 Sample 78 198 Positive Positive
K191099 - Page 17 of 19

[Table 1 on page 17]
					cutoff
concentration)	
AMP 1000	Positive	0	0	1	4	36
	Negative	16	20	3	0	0
Secobarbital
300	Positive	0	0	1	2	37
	Negative	18	17	4	1	0
Oxazepam
300	Positive	0	0	2	3	36
	Negative	19	17	2	1	0
COC 300	Positive	0	0	1	3	37
	Negative	20	15	4	0	0
THC 50	Positive	0	0	0	2	36
	Negative	21	15	4	2	0
MTD 300	Positive	0	0	1	2	37
	Negative	18	17	4	1	0
MET 1000	Positive	0	0	2	3	36
	Negative	22	14	2	1	0
MDMA 500	Positive	0	0	1	4	36
	Negative	25	11	3	0	0
MOP 300	Positive	0	0	1	2	37
	Negative	21	14	4	1	0
MOP 2000	Positive	0	0	0	4	35
	Negative	20	17	3	1	0
PPX 300	Positive	0	0	1	2	36
	Negative	25	11	3	2	0
OXY 100	Positive	0	0	1	3	37
	Negative	21	14	4	0	0
Nortriptylin
e 1000	Positive	0	0	0	2	36
	Negative	23	13	4	2	0
BUP 10	Positive	0	0	0	2	36
	Negative	21	15	4	2	0
PCP 25	Positive	0	0	2	3	16
	Negative	20	16	4	0	0

[Table 2 on page 17]
Tested Drug	Cut-off	Sample Number	LC/MS
Result	Atlas Multi –
Screening DOA
panel Test
Results	Atlas Multi –
Screening DOA
Cup Test
Results
AMP	1000	Sample 23	855	Positive	Positive
Secobarbital	300	Sample 51	287	Positive	Positive
Secobarbital	300	Sample 71	348	Negative	Negative
Oxazepam	300	Sample 16	330	Negative	Negative
Oxazepam	300	Sample 37	299	Positive	Positive
Oxazepam	300	Sample 78	198	Positive	Positive

--- Page 18 ---
COC 300 Sample 67 294 Positive Positive
THC 50 Sample 43 55 Negative Negative
THC 50 Sample 66 56 Negative Negative
MTD 300 Sample 43 304 Negative Negative
MTD 300 Sample 80 293 Positive Positive
MET 1000 Sample 6 1006 Negative Negative
MET 1000 Sample 34 992 Positive Positive
MET 1000 Sample 63 989 Positive Positive
MDMA 500 Sample 43 501 Positive Positive
MOP 300 Sample 7 318 Negative Negative
MOP 300 Sample 57 292 Positive Positive
MOP 2000 Sample 4 2007 Negative Negative
PCP 25 Sample 10 24 Positive Positive
PCP 25 Sample 26 22 Positive Positive
PPX 300 Sample 15 314 Negative Negative
PPX 300 Sample 42 302 Negative Negative
PPX 300 Sample 47 289 Positive Positive
OXY 100 Sample 25 98 Positive Positive
Nortriptyline 1000 Sample 61 1010 Negative Negative
Nortriptyline 1000 Sample 78 1013 Negative Negative
BUP 10 Sample 3 11 Negative Negative
BUP 10 Sample 78 11 Negative Negative
2. Matrix Comparison:
Urine is the only matrix
C Clinical Studies:
1. Clinical Sensitivity:
Not Applicable
2. Clinical Specificity:
Not Applicable
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
None
D Clinical Cut-Off:
Not Applicable
E Expected Values/Reference Range:
Not Applicable
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
K191099 - Page 18 of 19

[Table 1 on page 18]
COC	300	Sample 67	294	Positive	Positive
THC	50	Sample 43	55	Negative	Negative
THC	50	Sample 66	56	Negative	Negative
MTD	300	Sample 43	304	Negative	Negative
MTD	300	Sample 80	293	Positive	Positive
MET	1000	Sample 6	1006	Negative	Negative
MET	1000	Sample 34	992	Positive	Positive
MET	1000	Sample 63	989	Positive	Positive
MDMA	500	Sample 43	501	Positive	Positive
MOP	300	Sample 7	318	Negative	Negative
MOP	300	Sample 57	292	Positive	Positive
MOP	2000	Sample 4	2007	Negative	Negative
PCP	25	Sample 10	24	Positive	Positive
PCP	25	Sample 26	22	Positive	Positive
PPX	300	Sample 15	314	Negative	Negative
PPX	300	Sample 42	302	Negative	Negative
PPX	300	Sample 47	289	Positive	Positive
OXY	100	Sample 25	98	Positive	Positive
Nortriptyline	1000	Sample 61	1010	Negative	Negative
Nortriptyline	1000	Sample 78	1013	Negative	Negative
BUP	10	Sample 3	11	Negative	Negative
BUP	10	Sample 78	11	Negative	Negative

--- Page 19 ---
IX Conclusion:
The submitted information in this premarket notification is complete and support a substantial
equivalence decision.
K191099 - Page 19 of 19